Literature DB >> 27733423

Enhanced Protective Immunogenicity of Homodimeric Borrelia burgdorferi Outer Surface Protein C.

Diane G Edmondson1, Sabitha Prabhakaran1, Steven J Norris1, Amy J Ullmann2, Joe Piesman2, Marc Dolan2, Christian Probst3, Christiane Radzimski3, Winfried Stöcker3, Lars Komorowski4.   

Abstract

Lyme borreliosis is caused by tick-transmitted spirochetes of the Borrelia burgdorferi sensu lato group and is the most common vector-borne disease in the United States and Europe. Outer surface protein C (OspC) is a 23-kDa outer surface lipoprotein expressed during spirochete transmission from the tick to the vertebrate host. In a previous study, we found that immunization with a recombinant disulfide-bridged dimeric form of OspC (D-OspC) stimulates increased antibody responses relative to immunization with commonly employed monomeric OspC. Here, we report that mice immunized with dimeric OspC proteins also exhibited enhanced protection against infection with the cognate B. burgdorferi strain. Mice were protected by four immunizations containing as little as 100 ng of dimeric OspC, suggesting that this form of the protein can induce protective immunity within a dose range reasonable for a human or veterinary vaccine. In contrast, monomeric OspC was only partially protective at much higher doses. IgG subclass analysis revealed that D-OspC-immunized animals mainly possessed anti-OspC-IgG1. In contrast, infected animals develop anti-OspC restricted to the IgG3 isotype. A subset of antibodies generated by dimeric OspC immunization did not recognize the monomeric variant, indicating that unique epitopes exist on the dimeric form. Moreover, monoclonal antibodies that recognized only dimeric OspC protected mice from B. burgdorferi challenge, whereas another monoclonal that recognized both immunogens was not protective. These studies suggest that this dimeric OspC presents distinctive epitopes that generate antibodies protective against B. burgdorferi infection and could be a useful vaccine component.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Borrelia; Borrelia burgdorferi; ELISA; Lyme disease; OspC; immunoblot; vaccine

Mesh:

Substances:

Year:  2017        PMID: 27733423      PMCID: PMC5216437          DOI: 10.1128/CVI.00306-16

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  66 in total

1.  Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells.

Authors:  Megan K L MacLeod; Amy S McKee; Alexandria David; Jieru Wang; Robert Mason; John W Kappler; Philippa Marrack
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

2.  Analysis of antibody response in humans to the type A OspC loop 5 domain and assessment of the potential utility of the loop 5 epitope in Lyme disease vaccine development.

Authors:  Eric L Buckles; Christopher G Earnhart; Richard T Marconi
Journal:  Clin Vaccine Immunol       Date:  2006-10

3.  Temporal changes in outer surface proteins A and C of the lyme disease-associated spirochete, Borrelia burgdorferi, during the chain of infection in ticks and mice.

Authors:  T G Schwan; J Piesman
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

4.  The Lyme disease agent exploits a tick protein to infect the mammalian host.

Authors:  Nandhini Ramamoorthi; Sukanya Narasimhan; Utpal Pal; Fukai Bao; Xiaofeng F Yang; Durland Fish; Juan Anguita; Michael V Norgard; Fred S Kantor; John F Anderson; Raymond A Koski; Erol Fikrig
Journal:  Nature       Date:  2005-07-28       Impact factor: 49.962

5.  A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.

Authors:  Nina Wressnigg; P Noel Barrett; Eva-Maria Pöllabauer; Maria O'Rourke; Daniel Portsmouth; Michael G Schwendinger; Brian A Crowe; Ian Livey; Thomas Dvorak; Bernhard Schmitt; Markus Zeitlinger; Herwig Kollaritsch; Meral Esen; Peter G Kremsner; Tomas Jelinek; Roland Aschoff; Roland Weisser; Ingomar F K Naudts; Gerald Aichinger
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

6.  Antialarmin effect of tick saliva during the transmission of Lyme disease.

Authors:  Claire Marchal; Frederic Schramm; Aurélie Kern; Benjamin J Luft; Xiaohua Yang; Tim J Schuijt; Tim Schuijt; Joppe W Hovius; Joppe Hovius; Benoît Jaulhac; Nathalie Boulanger
Journal:  Infect Immun       Date:  2010-12-06       Impact factor: 3.441

Review 7.  The role of Borrelia burgdorferi outer surface proteins.

Authors:  Melisha R Kenedy; Tiffany R Lenhart; Darrin R Akins
Journal:  FEMS Immunol Med Microbiol       Date:  2012-05-21

8.  Comprehensive seroprofiling of sixteen B. burgdorferi OspC: implications for Lyme disease diagnostics design.

Authors:  Larisa Ivanova; Iva Christova; Vera Neves; Miguel Aroso; Luciana Meirelles; Dustin Brisson; Maria Gomes-Solecki
Journal:  Clin Immunol       Date:  2009-07-02       Impact factor: 3.969

9.  High- and low-infectivity phenotypes of clonal populations of in vitro-cultured Borrelia burgdorferi.

Authors:  S J Norris; J K Howell; S A Garza; M S Ferdows; A G Barbour
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

10.  Assessment of the potential contribution of the highly conserved C-terminal motif (C10) of Borrelia burgdorferi outer surface protein C in transmission and infectivity.

Authors:  Christopher G Earnhart; DeLacy V L Rhodes; Alexis A Smith; Xiuli Yang; Brittney Tegels; Jason A Carlyon; Utpal Pal; Richard T Marconi
Journal:  Pathog Dis       Date:  2014-02-03       Impact factor: 3.166

View more
  8 in total

1.  Epitope mapping of Borrelia burgdorferi OspC protein in homodimeric fold.

Authors:  Adam Norek; Lubomír Janda
Journal:  Protein Sci       Date:  2017-02-11       Impact factor: 6.725

2.  Analysis of the antigenic determinants of the OspC protein of the Lyme disease spirochetes: Evidence that the C10 motif is not immunodominant or required to elicit bactericidal antibody responses.

Authors:  Jerilyn R Izac; Andrew C Camire; Christopher G Earnhart; Monica E Embers; Rebecca A Funk; Edward B Breitschwerdt; Richard T Marconi
Journal:  Vaccine       Date:  2019-03-25       Impact factor: 3.641

3.  Maximum antigen diversification in a lyme bacterial population and evolutionary strategies to overcome pathogen diversity.

Authors:  Lia Di; Saymon Akther; Edgaras Bezrucenkovas; Larisa Ivanova; Brian Sulkow; Bing Wu; Saad Mneimneh; Maria Gomes-Solecki; Wei-Gang Qiu
Journal:  ISME J       Date:  2021-08-19       Impact factor: 10.302

4.  Immunization of mice with Borrelia burgdorferi lp54 gene encoded recombinant proteins does not provide protection against tick transmitted infectious challenge.

Authors:  Kevin S Brandt; Robert D Gilmore
Journal:  Vaccine       Date:  2017-09-01       Impact factor: 3.641

Review 5.  When a patient suspected with juvenile idiopathic arthritis turns out to be diagnosed with an infectious disease - a review of Lyme arthritis in children.

Authors:  Krzysztof Orczyk; Joanna Świdrowska-Jaros; Elżbieta Smolewska
Journal:  Pediatr Rheumatol Online J       Date:  2017-05-08       Impact factor: 3.054

6.  Overcoming Symmetry Mismatch in Vaccine Nanoassembly through Spontaneous Amidation.

Authors:  Rolle Rahikainen; Pramila Rijal; Tiong Kit Tan; Hung-Jen Wu; Anne-Marie C Andersson; Jordan R Barrett; Thomas A Bowden; Simon J Draper; Alain R Townsend; Mark Howarth
Journal:  Angew Chem Int Ed Engl       Date:  2020-10-27       Impact factor: 15.336

7.  Correlation between COVID-19 severity and previous exposure of patients to Borrelia spp.

Authors:  Alina Szewczyk-Dąbrowska; Wiktoria Budziar; Marek Harhala; Krzysztof Baniecki; Aleksandra Pikies; Natalia Jędruchniewicz; Zuzanna Kaźmierczak; Katarzyna Gembara; Tomasz Klimek; Wojciech Witkiewicz; Artur Nahorecki; Kamil Barczyk; Marlena Kłak; Urszula Grata-Borkowska; Krystyna Dąbrowska
Journal:  Sci Rep       Date:  2022-09-24       Impact factor: 4.996

8.  Development and optimization of OspC chimeritope vaccinogens for Lyme disease.

Authors:  Jerilyn R Izac; Nathaniel S O'Bier; Lee D Oliver; Andrew C Camire; Christopher G Earnhart; DeLacy V LeBlanc Rhodes; Brandon F Young; Stuart R Parnham; Christopher Davies; Richard T Marconi
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.